


THE WHITE HOUSE WASHINGTON

# **COVID-19** Press Briefing

March 3, 2021







# New Admissions of Patients with Confirmed COVID-19

#### August 1, 2020 – February 28, 2021



41,413

New Admissions on 2/28/21

4,606

Peak in New Admissions (1/5/21)

18,008

Change in 7-Day Average of New Admissions


-11.9%

Current 7-Day Average of New Admissions (2/22/21 - 2/28/21)

5,755

```
Prior 7-Day Average of New Admissions (2/15/21 - 2/21/21)
```

6,529




• Latest • New Admissions • Peak — 7-Day Moving Average - New Admissions



# Daily Change in COVID-19 Deaths, United States

January 22, 2020 – March 1, 2021









### **Selected SARS-CoV-2 Variants**

# Characteristics

<ul> <li>Increased transmissibility</li> <li>Possibly increased disease severity</li> <li>Covered well by currently authorized vaccines</li> </ul>
<ul> <li>Possibly increased transmissibility</li> <li>Moderately to severely reduced vaccine efficacy for some vaccines</li> <li>In vitro studies suggest neutralization by certain monoclonal antibodies may be severely reduced</li> </ul>
<ul> <li>Preliminary reports of increased transmissibility</li> <li>Antibodies elicited by previous infection or vaccine may be less effective</li> </ul>
Preliminary reports of increased transmissibility and disease severity
Variable loss of neutralizing activity by some monoclonal and vaccine-induced antibodies



Lineage

### Selected Vaccination Strategies to Address SARS-CoV-2 Variants


Ramp up vaccination with 1st and 2nd doses of current EUA vaccines

Booster doses

- Variant-specific vaccines
  - Pan-CoV "universal" vaccines



#### Pfizer/Biontech COVID-19 Vaccine: Neutralizing Antibody Titers After First and Second Dose







January 26, 2021

# Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization

P Wang, DD Ho et al.



### **Pfizer-Biontech Booster Study**

3rd dose (30 µg) of Pfizer-Biontech COVID-19 vaccine, BNT162b2, will be given to participants in phase 1 trial to evaluate safety, tolerability and immunogenicity

Study will evaluate up to 144 participants in two age cohorts, 18-55 and 65-85 years of age



February 24, 2021



# Moderna To Begin Clinical Trials of COVID Booster Shots for Variant From South Africa, Sends to NIH for Study



### Variant Vaccine Strategy – Upcoming NIAID Clinical Trial in Collaboration with Moderna

- Moderna has developed a variant-specific vaccine candidate mRNA-1273.351 against the variant known as B.1.351 first identified in the Republic of South Africa
- NIAID and Moderna will conduct a phase 1 study of the safety and immunogenicity of mRNA-1273.351 in naïve and previously vaccinated adults
- Planned study launch: mid-March 2021



## The "Holy Grail" – A Universal Coronavirus Vaccine





Question for @WHCOVIDResponse:

What is considered "fully vaccinated" after receiving the Johnson & Johnson vaccine?

We know with the other two it's considered "second dose plus two weeks."

When does protection kick in with J & J?

11:29 AM · Mar 1, 2021 · Twitter for iPhone





THE WHITE HOUSE WASHINGTON

